Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-04
-
The earliest appearance of tumors
2023-12-05
The earliest appearance of tumors occurred at 12 months and the latest at 24 months, with an average onset at 18 months (Fig. 1B). This would be roughly equivalent to cancer presenting in a patient between 60 and 70 years of age. In transgenic animals, autotaxin cpi-613 was relatively increased in s
-
The inhibition of ACLY induces
2023-12-04
The inhibition of ACLY induces an anticancer effect that has been reported to be involved in mitochondrial reactive oxygen species (ROS) generation [14], [16], dual blockade of mitogen-activated protein kinase and phosphatidylinositol-3-kinase/AKT pathways [11], and the glycolytic phenotype of tumor
-
br Acknowledgments This work was
2023-12-04
Acknowledgments This work was supported by the Swiss National Science Foundation. 15-Lipoxygenase 1 (15-LOX-1) is a nonheme, iron-containing enzyme predominantly expressed in reticulocytes, eosinophils, macrophages, mast cells, and bronchial epithelial cells . 15-LOX-1 is a key enzyme involved
-
br STAR Methods br Author Contributions br
2023-12-04
STAR★Methods Author Contributions Acknowledgments We thank Craig D. Wenger and Neva C. Durand for helpful advice, guidance, and discussions. D.H.P. is supported by the NIH National Human Genome Research Institute (NHGRI) (grant R00HG008662) and the Damon Runyon Cancer Research Foundation (D
-
However from our meta analysis
2023-12-04
However, from our meta-analysis emerge some strategic considerations for the continued use of antiangiogenic drugs for glioblastoma patients: Conflict of interest Funding Introduction Angiogenesis is a physiological process involving the formation of new blood vessels from pre-existing blo
-
br Conclusions In summary we report
2023-12-04
Conclusions In summary, we report a novel preliminary finding of a potential racial difference in the association of Cd-content and AR expression in prostate cancer that will need to be confirmed in larger studies. Although the association of Cd and AR protein expression is not strong in tumor ti
-
Here we found that AMPK directly phosphorylates EZH at
2023-12-04
Here we found that AMPK directly phosphorylates EZH2 at Thr311 to disrupt its interaction with SUZ12 and to inhibit PRC2 enzymatic activity, which is supported by the increased expression of PRC2-repressed genes. Furthermore, the T311E-EZH2 mutant that mimics AMPK-mediated phosphorylation status sup
-
br Acknowledgements This work was
2023-12-04
Acknowledgements This work was supported by Programme Grants from the MRC and the Wellcome Trust (SGC-C and MF). CB was in receipt of a Marie Curie Intra-European Fellowship during part of this work. We thank past and present members of our group for numerous valuable discussions throughout these
-
There is a growing body
2023-12-04
There is a growing body of evidence showing that pentobarbital causes memory disorders [3], [4], [5]. Our results that a single injection of pentobarbital into bilateral hippocampus significantly impaired hippocampus-dependent spatial memory retrieval (Fig. 1) add support to that evidence. Previous
-
A characteristic of iron present in brain fluids is
2023-12-04
A characteristic of iron present in brain fluids is considerable differences between measured values of ferritin and transferrin and the total iron content value (Table 1). Variation of the latter is compatible with differences in individual metabolisms. However differences between total iron conten
-
Recently a Phase III study demonstrated that alectinib
2023-12-04
Recently, a Phase III study demonstrated that alectinib, the second-generation ALK inhibitor, might have a better response to ALK-rearrangement patients than crizotinib [10]. Should alectinib replace crizotinib as the frontline treatment for ALK-rearranged patients? Or should those patients be treat
-
As one of emerging high throughout methods metabolomics dete
2023-12-04
As one of emerging high-throughout methods, metabolomics detects metabolites which are ultimate response of biological systems to environmental changes [14]. Metabolomics uncovers metabolic alteration at the systems level. Comparison of global metabolic profiling reflects some unidentified biologica
-
The lack of specific PARP inhibitors prevents our understand
2023-12-04
The lack of specific PARP inhibitors prevents our understanding of how TIPARP or perhaps other PARPs affect AHR signaling. Current inhibitors are based on NAM and were designed to inhibit PARP1 [59]. Many of them do not effectively inhibit mono-ADP-ribosyltransferases and their ability to inhibit TI
-
AdK as an important upstream
2023-12-04
AdK as an important upstream regulator of adenosine-based homeostasis represents a promising drug target since it leads to an increase in adenosine concentrations. Taking into account that the adenosine formation is only increased in affected tissues under stress with high adenosine levels, AdK inhi
-
br Methods br Transparency document br Introduction Epinephr
2023-12-04
Methods Transparency document Introduction Epinephrine (EP) is a critical hormone and catecholamine neurotransmitter in nervous system of mammals.1, 2, 3 It has been known to accelerate and regulate heartbeat, blood pressure, bronchodilation, mydriasis, blood sugar and lipolysis, and can he
14208 records 223/948 page Previous Next First page 上5页 221222223224225 下5页 Last page